These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

593 related items for PubMed ID: 2890164

  • 1. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Schally AV, Redding TW.
    Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
    [Abstract] [Full Text] [Related]

  • 2. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model.
    Yano T, Pinski J, Szepeshazi K, Milovanovic SR, Groot K, Schally AV.
    Prostate; 1992 Oct; 20(4):297-310. PubMed ID: 1351672
    [Abstract] [Full Text] [Related]

  • 3. Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.
    Schally AV, Kook AI, Monje E, Redding TW, Paz-Bouza JI.
    Proc Natl Acad Sci U S A; 1986 Nov; 83(22):8764-8. PubMed ID: 2946045
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
    Milovanovic SR, Radulovic S, Groot K, Schally AV.
    Prostate; 1992 Nov; 20(4):269-80. PubMed ID: 1376910
    [Abstract] [Full Text] [Related]

  • 5. Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.
    Radulovic S, Comaru-Schally AM, Milovanovic S, Schally AV.
    Pancreas; 1993 Jan; 8(1):88-97. PubMed ID: 8093555
    [Abstract] [Full Text] [Related]

  • 6. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin.
    Kadar T, Redding TW, Ben-David M, Schally AV.
    Proc Natl Acad Sci U S A; 1988 Feb; 85(3):890-4. PubMed ID: 2893378
    [Abstract] [Full Text] [Related]

  • 7. Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model.
    Schally AV, Redding TW.
    Proc Natl Acad Sci U S A; 1985 Apr; 82(8):2498-502. PubMed ID: 3157990
    [Abstract] [Full Text] [Related]

  • 8. Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone.
    Paz-Bouza JI, Redding TW, Schally AV.
    Proc Natl Acad Sci U S A; 1987 Feb; 84(4):1112-6. PubMed ID: 2881296
    [Abstract] [Full Text] [Related]

  • 9. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
    Redding TW, Schally AV, Radulovic S, Milovanovic S, Szepeshazi K, Isaacs JT.
    Cancer Res; 1992 May 01; 52(9):2538-44. PubMed ID: 1568223
    [Abstract] [Full Text] [Related]

  • 10. Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin.
    Szende B, Zalatnai A, Schally AV.
    Proc Natl Acad Sci U S A; 1989 Mar 01; 86(5):1643-7. PubMed ID: 2564204
    [Abstract] [Full Text] [Related]

  • 11. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.
    Szepeshazi K, Milovanovic S, Lapis K, Groot K, Schally AV.
    Breast Cancer Res Treat; 1992 Mar 01; 21(3):181-92. PubMed ID: 1355375
    [Abstract] [Full Text] [Related]

  • 12. Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model.
    Redding TW, Schally AV.
    Prostate; 1985 Mar 01; 6(3):219-32. PubMed ID: 3157927
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of growth of a prolactin and growth hormone-secreting pituitary tumor in rats by D-tryptophan-6 analog of luteinizing hormone-releasing hormone.
    Torres-Aleman I, Redding TW, Schally AV.
    Proc Natl Acad Sci U S A; 1985 Feb 01; 82(4):1252-6. PubMed ID: 2858096
    [Abstract] [Full Text] [Related]

  • 14. Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D-Trp-6-LH-RH.
    Zalatnai A, Paz-Bouza JI, Redding TW, Schally AV.
    Prostate; 1988 Feb 01; 12(1):85-98. PubMed ID: 2894651
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.
    Korkut E, Bokser L, Comaru-Schally AM, Groot K, Schally AV.
    Proc Natl Acad Sci U S A; 1991 Feb 01; 88(3):844-8. PubMed ID: 1992476
    [Abstract] [Full Text] [Related]

  • 16. Treatment of N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160 microcapsules.
    Zalatnai A, Schally AV.
    Cancer Res; 1989 Apr 01; 49(7):1810-5. PubMed ID: 2564312
    [Abstract] [Full Text] [Related]

  • 17. Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies.
    Schally AV, Srkalovic G, Szende B, Redding TW, Janaky T, Juhasz A, Korkut E, Cai RZ, Szepeshazi K, Radulovic S.
    J Steroid Biochem Mol Biol; 1990 Dec 20; 37(6):1061-7. PubMed ID: 1981009
    [Abstract] [Full Text] [Related]

  • 18. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma.
    Srkalovic G, Szende B, Redding TW, Groot K, Schally AV.
    Proc Soc Exp Biol Med; 1989 Dec 20; 192(3):209-18. PubMed ID: 2574866
    [Abstract] [Full Text] [Related]

  • 19. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Pinski J, Halmos G, Szepeshazi K, Schally AV.
    Cancer; 1993 Dec 01; 72(11):3263-70. PubMed ID: 8242552
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones.
    Redding TW, Schally AV.
    Proc Natl Acad Sci U S A; 1984 Jan 01; 81(1):248-52. PubMed ID: 6141560
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.